China will add 111 drugs to its national medical reimbursement list this year, with a focus on including treatments for infections, COVID-19 drugs and advanced medications for children's diseases and tumors, the National Healthcare Security Administration said last week.
Among them, 108 drugs were added following successful negotiations with manufacturers, with average prices slashed by 60.1 percent.
Meanwhile, three drugs whose licenses have been revoked will be removed from the list, putting the total number of drugs on the list at 2,967.
The administration has updated the list annually since 2018, during which time 361 novel and high-quality drugs have been added, gradually filling the gaps in affordable access to drugs for tumors, chronic diseases, rare illnesses and children.
The latest update includes 23 cancer drugs, 17 treatments for infections, seven for rare diseases and two for COVID-19.
The two COVID-19 drugs are Azvudine, a homegrown oral pill, and Qingfei Paidu granules, a traditional Chinese medicine.
